Intra-Cellular Therapies is a biopharmaceutical company focused on developing and commercializing drugs for psychiatric and neurological disorders. Its sole commercial product is CAPLYTA (lumateperone), an oral once-daily pill approved to treat schizophrenia and bipolar depression in adults. CAPLYTA is differentiated within the antipsychotic class by a tolerability profile similar to placebo on metabolic and movement disorder measures — a meaningful advantage given that side effects are the primary reason patients discontinue antipsychotics. Revenue is generated entirely from CAPLYTA net product sales in the U.S., driven by prescription volume and net realized price. The company sells through a national sales force targeting psychiatrists, nurse practitioners, and primary care physicians, and distributes through three wholesale drug distributors. Intra-Cellular pays Bristol-Myers Squibb tiered royalties of 5–9% on CAPLYTA sales under an exclusive license for the lumateperone compound. The most significant near-term growth driver is a potential FDA approval for CAPLYTA as an adjunctive treatment for major depressive disorder (MDD), supported by two positive Phase 3 trials and an sNDA accepted for FDA review in early 2025. Adding MDD would expand CAPLYTA's addressable market from roughly half to roughly 80% of U.S. antipsychotic prescriptions. The pipeline also includes ITI-1284, a deuterated lumateperone formulation in Phase 2 studies for generalized anxiety disorder and Alzheimer's disease behavioral symptoms. Note: Johnson & Johnson announced a definitive agreement to acquire Intra-Cellular for ~$14.6B in January 2025.